Astragaloside A Protects Against Photoreceptor Degeneration in Part Through Suppressing Oxidative Stress and DNA Damage-Induced Necroptosis and Inflammation in the Retina
Mei Li,Jing Xu,Yujue Wang,Xiaoye Du,Teng Zhang,Yu Chen
DOI: https://doi.org/10.2147/jir.s362401
IF: 4.5
2022-05-21
Journal of Inflammation Research
Abstract:Mei Li, 1 Jing Xu, 1, 2 Yujue Wang, 1 Xiaoye Du, 1, 2 Teng Zhang, 1, 2 Yu Chen 1– 3 1 Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200427, People's Republic of China; 2 Clinical Research Institute of Integrative Medicine, Shanghai Academy of Traditional Chinese Medicine, Shanghai, 200437, People's Republic of China; 3 Laboratory of Clinical and Molecular Pharmacology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200427, People's Republic of China Correspondence: Yu Chen, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, 110 Ganhe Road, Shanghai, 200437, People's Republic of China, Tel +86 21 5598 1009, Fax +86 21 5598 1009, Email Purpose: Photoreceptors are specialized retinal neurons responsible for phototransduction. Loss of photoreceptors directly leads to irreversible vision impairment. Pharmacological therapies protecting against photoreceptor degeneration are clinically lacking. Oxidative stress and inflammation are common mechanisms playing important roles in the pathogenesis of photoreceptor degeneration. Astragaloside A (AS-A) is a naturally occurring antioxidant and anti-inflammatory agent with neuroprotective activities. However, the photoreceptor protective effects of AS-A remain unknown. The current study thus aims to illustrate the pharmacological potentials of AS-A in protecting against photoreceptor degeneration. Methods: BALB/c and C57/BL6J mice were exposed to bright light and DNA alkylating agent methyl methanesulfonate (MMS) to develop oxidative stress and DNA damage-mediated photoreceptor degeneration, respectively. Microstructural, morphological and functional assessments were performed to directly evaluate the photoreceptor protective effects of AS-A. Ultrastructural and molecular changes in the retina were examined to better understand the pharmacological mechanisms of AS-A in protecting against photoreceptor degeneration. Results: AS-A protected against bright light-induced photoreceptor impairment. Bright light-induced retinal oxidative stress and photoreceptor cell death were attenuated by AS-A treatment. AS-A treatment mitigated bright light-induced DNA damage, activation of poly (ADP-ribose) polymerase (PARP) and nuclear dislocation of high mobility group box 1 (HMGB1) in photoreceptors. AS-A broadly counteracted bright light-altered retinal gene expression profiles. In particular, AS-A decreased the retinal expression of genes involved in necroptosis and inflammatory responses. Bright light-induced microglial activation was also suppressed as a result of AS-A treatment. Furthermore, AS-A attenuated MMS-induced photoreceptor morphological impairment, elevated expression of pro-necroptotic and proinflammatory genes as well as microglial activation in the retina. Conclusion: The work here demonstrates for the first time that AS-A protects against photoreceptor degeneration in part through mitigating oxidative stress and DNA damage-induced necroptosis and inflammatory responses in the retina. Keywords: retinal degeneration, photooxidative stress, photoreceptor protection, programmed cell death, microglial activation Photoreceptors are the first-order retinal neurons that carry out light detection and phototransduction functions, playing an essential role in initiating vision. 1 Photoreceptor degeneration is responsible for irreversible and progressive vision impairment in patients with age-related macular degeneration (AMD) and inherited retinal degeneration such as retinitis pigmentosa. 2,3 A number of therapies have been evaluated in clinical trials and proven to be either ineffective or inconclusive regarding the efficacy to prevent the loss of photoreceptors in dry AMD. Ongoing clinical trials are also available for the treatment of dry AMD. However, proper photoreceptor protective therapies have not been officially approved for clinical usage to prevent or delay the progression of photoreceptor degeneration. 4 Photoreceptor degenerative disorders can be caused by mutations in the functional genes, environmental insults or a combination of both genetic and environmental factors. Regardless of the etiologies, programmed cell death triggered by oxidative stress is a common mechanism underlying the loss of photoreceptors. 5 Moreover, photoreceptor degeneration is often accompanied and further aggravated by excessive inflammatory responses primarily mediated by activated microglial cel -Abstract Truncated-
immunology